LOTRIMIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LOTRIMIN (LOTRIMIN).
Clotrimazole inhibits fungal cytochrome P450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
| Metabolism | Hepatic metabolism via CYP3A4 and CYP2C9; excreted in feces and urine as metabolites. |
| Excretion | Approximately 70% of absorbed dose is excreted in feces as unchanged drug and metabolites; about 20% is excreted renally as metabolites with less than 1% unchanged. Biliary excretion is a minor route. |
| Half-life | Terminal elimination half-life is approximately 20-50 hours. Dose adjustments not required in renal impairment, but caution in hepatic impairment. |
| Protein binding | Approximately 98% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Volume of distribution is approximately 2.5-4.0 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Topical: minimal systemic absorption (<0.5%). Oral: not available; vaginal: approximately 3-10% systemic absorption. |
| Onset of Action | Topical: pruritus relief within 24-72 hours; clinical improvement in 1-2 weeks. |
| Duration of Action | Duration of antifungal effect persists for 24 hours after topical application. Treatment should continue for at least 2 weeks to prevent recurrence. |
Clotrimazole 1% cream or solution applied topically to affected area twice daily for 2-4 weeks. For vaginal tablets: 100 mg intravaginally once daily for 7 days or 500 mg single dose. For troches: 10 mg troche dissolved slowly in mouth five times daily for 14 days.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for topical or vaginal use. For troches, no data available; however, systemic absorption is minimal. |
| Liver impairment | No dose adjustment required for topical or vaginal use. For troches, use with caution in severe hepatic impairment due to limited data. |
| Pediatric use | Topical: Apply to affected area twice daily for 2-4 weeks (safe for all ages). Vaginal: Not recommended in prepubertal children. Troches: Not recommended for children under 5 years due to risk of choking; for children ≥5 years, same dose as adults (10 mg troche five times daily). |
| Geriatric use | No specific dose adjustment required. Use same dosing as adults. Consider skin fragility with topical application. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for LOTRIMIN (LOTRIMIN).
| Breastfeeding | Minimal systemic absorption after topical or vaginal use leads to negligible excretion into breast milk. M/P ratio is not applicable due to undetectable levels. Suitable for use during breastfeeding. No adverse effects reported in nursing infants. |
| Teratogenic Risk | Clotrimazole (LOTRIMIN) topical use is not associated with increased risk of major congenital malformations. Systemic absorption is minimal (<0.5% after vaginal or topical application). First trimester vaginal use has insufficient data, but no clear teratogenic signal. Second and third trimester vaginal use is considered safe. Overall, risk is low due to negligible systemic exposure. |
■ FDA Black Box Warning
None
| Common Effects | Eye irritation Watery eyes Burning sensation |
| Serious Effects |
Hypersensitivity to clotrimazole or any component of the formulation
| Precautions | For external use only; avoid contact with eyes; discontinue if hypersensitivity occurs; not for ophthalmic or oral use; use in pregnancy only if clearly needed (Category B). |
Loading safety data…
| Fetal Monitoring | No specific monitoring required beyond standard pregnancy care. For vaginal infections, clinical resolution of symptoms should be confirmed. No fetal monitoring needed due to low systemic absorption. |
| Fertility Effects | No known effects on fertility in animal studies. In humans, no data suggesting impairment of fertility with topical or vaginal use. Does not affect ovulation or reproductive function. |